Syon Capital LLC Takes $621,000 Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Syon Capital LLC purchased a new stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 19,455 shares of the company's stock, valued at approximately $621,000.

A number of other hedge funds have also made changes to their positions in APLS. Hsbc Holdings PLC increased its position in Apellis Pharmaceuticals by 7.9% during the 4th quarter. Hsbc Holdings PLC now owns 127,828 shares of the company's stock worth $4,080,000 after purchasing an additional 9,341 shares in the last quarter. Avoro Capital Advisors LLC increased its position in Apellis Pharmaceuticals by 10.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 12,222,222 shares of the company's stock worth $390,011,000 after purchasing an additional 1,111,111 shares in the last quarter. Tower Research Capital LLC TRC increased its position in Apellis Pharmaceuticals by 275.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 19,965 shares of the company's stock worth $637,000 after purchasing an additional 14,654 shares in the last quarter. Natixis purchased a new stake in Apellis Pharmaceuticals during the 4th quarter worth about $27,782,000. Finally, First Trust Advisors LP increased its position in Apellis Pharmaceuticals by 48.2% during the 4th quarter. First Trust Advisors LP now owns 25,645 shares of the company's stock worth $818,000 after purchasing an additional 8,344 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on APLS shares. Royal Bank of Canada lowered their price target on Apellis Pharmaceuticals from $24.00 to $21.00 and set a "sector perform" rating for the company in a report on Monday, April 21st. JPMorgan Chase & Co. upped their price objective on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an "overweight" rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $57.00 price objective on shares of Apellis Pharmaceuticals in a research note on Monday, March 3rd. The Goldman Sachs Group decreased their target price on Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. Finally, Wedbush decreased their target price on Apellis Pharmaceuticals from $30.00 to $29.00 and set a "neutral" rating for the company in a report on Monday, March 3rd. Eight analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $45.35.

Apellis Pharmaceuticals Stock Up 2.7 %

NASDAQ APLS traded up $0.47 on Monday, reaching $17.96. The company had a trading volume of 1,824,381 shares, compared to its average volume of 2,168,607. The firm has a market capitalization of $2.26 billion, a PE ratio of -8.85 and a beta of 0.85. Apellis Pharmaceuticals, Inc. has a 1 year low of $16.98 and a 1 year high of $49.38. The firm has a 50-day moving average of $22.70 and a 200-day moving average of $27.66. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm had revenue of $212.50 million during the quarter, compared to analysts' expectations of $197.92 million. During the same quarter in the prior year, the business earned ($0.73) EPS. Apellis Pharmaceuticals's quarterly revenue was up 45.2% compared to the same quarter last year. On average, equities research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 2,824 shares of the firm's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $29.52, for a total transaction of $83,364.48. Following the completion of the transaction, the chief executive officer now directly owns 415,695 shares of the company's stock, valued at $12,271,316.40. This trade represents a 0.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel David O. Watson sold 5,569 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total transaction of $139,781.90. Following the transaction, the general counsel now directly owns 138,730 shares of the company's stock, valued at approximately $3,482,123. This represents a 3.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,005 shares of company stock valued at $299,037 in the last ninety days. Corporate insiders own 6.80% of the company's stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).